Breakthrough in Roundup Dispute: Court Preliminarily Approves Bayer's $7.25 Billion Settlement

German pharmaceutical and chemical conglomerate Bayer AG has made significant progress in the long-running legal dispute over the herbicide Roundup. A judge in Missouri granted preliminary approval for a settlement worth $7.25 billion, aimed at resolving tens of thousands of claims regarding the alleged carcinogenic effects of glyphosate. This is a key element of the management's strategy to distance itself from the costly legacy of Monsanto, acquired in 2018. While this news brought some relief to the markets, the company's overall financial health remains alarming. Bayer reported a deepening net loss, a direct result of write-offs related to ongoing lawsuits and a challenging market environment. The Roundup dispute has persisted since Bayer's $63 billion acquisition of Monsanto. Since then, the company has paid out billions in compensation, and its market capitalization has drastically declined.In response to deteriorating results, the CEO announced a radical restructuring plan, including the elimination of another 4,700 jobs. Management has labeled 2026 as a "decisive year" for the company's future, signaling that without ending the wave of lawsuits and stabilizing the agricultural division, regaining profitability will be impossible. Meanwhile, other entities in the sector, such as Merck, are also reporting cautious forecasts for 2026, pointing to the negative impact of a weak dollar on the financial performance of the pharmaceutical industry in Europe. The situation on the Frankfurt stock exchange was stabilized only by the fact that the DAX index managed to stay above the 23,000-point level, despite the poor sentiment surrounding the chemical sector. „Bayer faces a pivotal challenge in 2026, which must become a turning point for our financial stability.” — Bill Anderson Bayer's management is trying to reassure shareholders by promising to maintain the dividend at its current level, aiming to stem further capital outflow. However, analysts remain skeptical, criticizing the company for overly optimistic assumptions about the pace of resolving lawsuits in the US. Against the backdrop of Bayer's problems, other German companies like Continental and Traton are also facing cost pressures, although in their case, the market reaction is milder due to better management of market expectations. The end of the first quarter of 2026 appears as a period of great uncertainty for German industry, where giants must redefine their strategies in the face of global economic and legal turbulence.